Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74275 | 0.83 | MAOB (0.67) | MAOBIDO1TSHRALDH1A1TRPA1 | |
| SCHEMBL10366617 | 0.77 | MAOB (0.75) | MAOBIDO1TSHRALDH1A1TRPA1 | |
| SCHEMBL4392839 | 0.77 | MAOB (0.75) | MAOBIDO1TSHRALDH1A1TRPA1 | |
| SCHEMBL2023419 | 0.74 | MAOB (0.55) | MAOBIDO1TSHRALDH1A1TRPA1 | |
| SCHEMBL1005335 | 0.74 | MAOB (0.55) | MAOBIDO1TSHRALDH1A1TRPA1 | |
| SCHEMBL3755335 | 0.74 | MAOB (0.55) | MAOBIDO1TSHRALDH1A1TRPA1 | |
| SCHEMBL118087 | 0.74 | MAOB (0.55) | MAOBIDO1TSHRALDH1A1TRPA1 | |
| SCHEMBL185486 | 0.74 | MAOB (0.55) | MAOBIDO1TSHRALDH1A1TRPA1 | |
| SCHEMBL365818 | 0.74 | MAOB (0.55) | MAOBIDO1CA1CA2ARG2 | |
| SCHEMBL3007954 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104884423-B | methanofullerene | 亚历克斯·菲利普·格雷厄姆·罗宾逊 | 2017-11-17 | — | — | CN | disclosed |
| CN-107087426-A | two-step photoresist composition and method | 亚历克斯·菲利普·格雷厄姆·罗宾逊 | 2017-08-22 | — | — | CN | disclosed |
| CN-102666095-B | Resin substrate with hard coat film and manufacture method thereof | ASAHI GLASS CO.,LTD. (JP) | 2016-02-24 | — | — | CN | disclosed |
| CN-104884423-A | methanofullerene | ROBINSON ALEX PHILIP GRAHAM | 2015-09-02 | — | — | CN | disclosed |
| CN-102695565-B | There is the manufacture method of the resin substrate of hard coat and there is the resin substrate of hard coat | ASAHI GLASS CO.,LTD. (JP) | 2015-08-19 | — | — | CN | disclosed |
| US-8664254-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8569351-B2 | Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity | THERAVANCE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130245087-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-09-19 | — | — | US | disclosed |
| US-20130096162-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-04-18 | — | — | US | disclosed |
| CN-102695565-A | Process for producing resin substrate having hard coating layer, and resin substrate having hard coating layer | ASAHI GLASS CO LTD | 2012-09-26 | — | — | CN | disclosed |
| CN-101215421-A | Radiation-sensitive resin composition | JSR CORP (JP) | 2008-07-09 | — | — | CN | disclosed |
| CN-100374506-C | Radiation-sensitive resin composition | JSR CORP (JP) | 2008-03-12 | — | — | CN | disclosed |
| CN-1196029-C | Positive radiation-sensitive composition | TORAY INDUSTRIES (JP) | 2005-04-06 | — | — | CN | disclosed |
| EP-1178958-A2 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-02-13 | — | — | EP | disclosed |
| CN-1332205-A | Radiation-sensitive resin composition | JSR CORP (JP) | 2002-01-23 | — | — | CN | disclosed |
| CN-1287630-A | Positive radiation-sensitive composition | TORAY INDUSTRIES (JP) | 2001-03-14 | — | — | CN | disclosed |
| WO-2000055125-A2 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| US-5674864-A | ANALGESICS; ENDOPEPTIDASE AND ENKEPHALINASE INHIBITORS; CARDIOTONIC, PSYCHOTROPIC AND HYPERTENSIVE AGENTS | ROUSSEL UCLAF (FR) | 1997-10-07 | — | — | US | disclosed |
| EP-0465369-B1 | N-substituted derivatives of alpha-mercapto alkylamines, process for their preparation and intermediates obtained, their use as medicaments and compositions containing them | ROUSSEL UCLAF (FR) | 1994-04-13 | — | — | EP | disclosed |
| EP-0465369-A1 | N-substituted derivatives of alpha-mercapto alkylamines, process for their preparation and intermediates obtained, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096162-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MAOB 152/4885IDO1 444/4885TSHR 331/4885 |
| US-20130245087-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | MAOB 161/4885IDO1 100/4885TSHR 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.